Abstract
Cyclophosphamide was introduced in 1958 in an effort to minimize the side effects of nitrogen mustard [2]. Cyclophosphamide (Cytoxan, Endoxan) is an alkylating agent which has been used for the treatment of a variety of non-malignant as well as malignant diseases [9].
It has also recently been the focus of considerable interest as an immunosuppressive agent, perhaps the most potent immunosuppressive drug that has been synthesized. Reports of urologic complications from this drug are haemorrhagic cystitis, vesical fibrosis and urothelial carcinoma.
Similar content being viewed by others
References
Adiga, K. M.: Bladder tumour after treatment for lymphoma.J. Med. Austral., 190 (1981).
Arnold, HI., Bourseaux, F.: Synthese und Abbau cytostatisch wirksamer zyklischer N-Phosphamidester des bis (beta-chloräthyl)-amins.Angew. Chem., 70, 539 (1958).
Brock, N., Stekar, J.: Verhütung urotoxischer Wirkungen von Cyclophosphamid und Ifosfamid durch Dimesna.Arzneim. Forsch., 32, 486 (1982).
Durkee, C., Benson, R.: Bladder cancer following administration of cyclophosphamide.Urology, 16, 145 (1980).
Elliott, R. W., Essenhigh, D. M., Morley, A. R.: Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit.Br. Med. J., 284, 1160 (1982).
Fairchild, W. V., Spence, C. R., Solomon, H. D., Gangai, M. P.: The incidence of bladder cancer after cyclophosphamide therapy.J. Urol., 122, 163 (1979).
Fuchs, E. F., Kay, R., Poole, R., Barry, J. M., Pearse, H. D.: Uroepithelial carcinoma in association with cyclophosphamide ingestion.J. Urol., 126, 544 (1981).
Garvin, D. D., Ball, Th. P.: Bladder malignancy in patient receiving cyclophosphamide for benign disease.Urology, 18, 80 (1981).
Gershwin, M. E., Goetzl, E. J., Steinberg, A. D.: Cyclophosphamide: use in practice.Ann. Intern. Med., 80, 531 (1974).
Moinuddin, S. M., Upton, D. W.: Urothelial carcinoma after cyclophosphamide therapy.J. Urol., 129, 143 (1983).
McDougal, W. S., Cramer, S. F., Miller, R.: Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease.Cancer, 48, 691 (1981).
Philips, F. S., Sternberg, S. S., Cronin, A. P., Vidal, P. M.: Cyclophosphamide and urinary bladder toxicity.Cancer Res., 21, 1577 (1961).
Pearson, R. M., Soloway, M. S.: Does cyclophosphamide induce bladder cancer?Urology, 11, 437 (1978).
Schiff, H. I., Finkel, M., Schapira, H. E.: Transitional cell carcinoma of the ureter associated with cyclophosphamide therapy for benign disease: A case report.J. Urol., 128, 1023 (1982).
Seltzer, S. E., Benazzi, R. B., Kearney, G. P.: Cyclophosphamide and carcinoma of bladder.Urology, 11, 352 (1978).
Worth, P. H. L.: Cyclophosphamide and the bladder.Br. Med. J., 3, 182 (1971).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kiesswetter, H., Baloch, N. & Flamm, J. Bladder carcinoma following cyclophosphamide therapy. International Urology and Nephrology 17, 139–142 (1985). https://doi.org/10.1007/BF02082484
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02082484